Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.

Mattsson N, Smith R, Strandberg O, Palmqvist S, Schöll M, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Blennow K, Jögi J, Hansson O.

Neurology. 2018 Jan 30;90(5):e388-e395. doi: 10.1212/WNL.0000000000004887. Epub 2018 Jan 10.

2.

In vivo retention of 18F-AV-1451 in corticobasal syndrome.

Smith R, Schöll M, Widner H, van Westen D, Svenningsson P, Hägerström D, Ohlsson T, Jögi J, Nilsson C, Hansson O.

Neurology. 2017 Aug 22;89(8):845-853. doi: 10.1212/WNL.0000000000004264. Epub 2017 Jul 28.

3.

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.

Mattsson N, Schöll M, Strandberg O, Smith R, Palmqvist S, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Jögi J, Blennow K, Hansson O.

EMBO Mol Med. 2017 Sep;9(9):1212-1223. doi: 10.15252/emmm.201707809.

4.

Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks.

Hansson O, Grothe MJ, Strandberg TO, Ohlsson T, Hägerström D, Jögi J, Smith R, Schöll M.

Front Neurosci. 2017 Mar 31;11:167. doi: 10.3389/fnins.2017.00167. eCollection 2017.

5.

Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology.

Hahn A, Schain M, Erlandsson M, Sjölin P, James GM, Strandberg OT, Hägerström D, Lanzenberger R, Jögi J, Olsson TG, Smith R, Hansson O.

J Nucl Med. 2017 Apr;58(4):623-631. doi: 10.2967/jnumed.116.174508. Epub 2016 Oct 20.

6.

Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy.

Smith R, Schain M, Nilsson C, Strandberg O, Olsson T, Hägerström D, Jögi J, Borroni E, Schöll M, Honer M, Hansson O.

Mov Disord. 2017 Jan;32(1):108-114. doi: 10.1002/mds.26813. Epub 2016 Oct 6.

PMID:
27709757
7.

Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.

Smith R, Wibom M, Olsson T, Hägerström D, Jögi J, Rabinovici GD, Hansson O.

J Alzheimers Dis. 2016;51(2):339-43. doi: 10.3233/JAD-151004.

PMID:
26836192
8.

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.

JAMA Neurol. 2014 Oct;71(10):1282-9. doi: 10.1001/jamaneurol.2014.1358.

PMID:
25155658
9.

CSF biomarkers correlate with cerebral blood flow on SPECT in healthy elderly.

Stomrud E, Forsberg A, Hägerström D, Ryding E, Blennow K, Zetterberg H, Minthon L, Hansson O, Londos E.

Dement Geriatr Cogn Disord. 2012;33(2-3):156-63. doi: 10.1159/000338185. Epub 2012 May 7.

PMID:
22722670
10.

A new automated method for analysis of rCBF-SPECT images based on the active-shape algorithm: normal values.

Hägerström D, Jakobsson D, Stomrud E, Andersson AM, Ryding E, Londos E, Minthon L, Rosén I, Edenbrandt L.

Clin Physiol Funct Imaging. 2012 Mar;32(2):114-9. doi: 10.1111/j.1475-097X.2011.01063.x. Epub 2011 Nov 8.

11.

A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction.

Puschmann A, Ross OA, Vilariño-Güell C, Lincoln SJ, Kachergus JM, Cobb SA, Lindquist SG, Nielsen JE, Wszolek ZK, Farrer M, Widner H, van Westen D, Hägerström D, Markopoulou K, Chase BA, Nilsson K, Reimer J, Nilsson C.

Parkinsonism Relat Disord. 2009 Nov;15(9):627-32. doi: 10.1016/j.parkreldis.2009.06.007. Epub 2009 Jul 25.

Supplemental Content

Loading ...
Support Center